<DOC>
	<DOCNO>NCT01670734</DOCNO>
	<brief_summary>Primary Objective : Study effect mild moderate hepatic impairment pharmacokinetics alirocumab SAR236553 ( REGN727 ) . Secondary Objectives : - Assess safety tolerability alirocumab SAR236553 ( REGN727 ) patient mild moderate hepatic impairment match subject normal hepatic function . - Assess pharmacodynamic profile alirocumab SAR236553 ( REGN727 ) patient hepatic impairment match subject normal hepatic function .</brief_summary>
	<brief_title>Pharmacokinetic Tolerability Alirocumab SAR236553 ( REGN727 ) Patients With Hepatic Impairment Healthy Subjects</brief_title>
	<detailed_description>Total duration study per subject ( exclude screen ) 12 week .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Male female , 18 75 year age , inclusive . Patients mild moderate hepatic impairment base ChildPugh score stable chronic liver disease . Healthy subject normal hepatic function . Exclusion criterion : Patients acute hepatitis , hepatic encephalopathy grade 2 , 3 , 4 . Patients history presence uncontrolled clinically relevant illness . Healthy subject history presence clinically relevant illness . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>